- Home
- GPRE vs ALT Comparison
GPRE vs ALT Comparison
Compare GPRE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPRE | ALT |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.4M | 576.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GPRE | ALT |
|---|---|---|
| Price | $9.71 | $5.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $8.69 | ★ $16.33 |
| AVG Volume (30 Days) | 1.2M | ★ 3.7M |
| Earning Date | 02-06-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,246,853,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.14 | $2.90 |
| 52 Week High | $12.31 | $9.59 |
Technical Indicators
Market Signals| Indicator | GPRE | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 52.68 |
| Support Level | $9.40 | $5.03 |
| Resistance Level | $9.87 | $6.03 |
| Average True Range (ATR) | 0.41 | 0.38 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 20.16 | 24.44 |
Price Performance
Historical ComparisonAbout GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.